Time from Screening Mammography to Biopsy and from Biopsy to Breast Cancer Treatment among Black and White, Women Medicare Beneficiaries Not Participating in a Health Maintenance Organization

Rebecca Selove, Barbara Kilbourne, Mary Kay Fadden, Maureen Sanderson, Maya Foster, Regina Offodile, Baqar Husaini, Charles Mouton, Robert S. Levine

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose There is a breast cancer mortality gap adversely affecting Black women in the United States. This study assessed the relationship between number of days between abnormal mammogram, biopsy, and treatment among Medicare (Part B) beneficiaries ages 65 to 74 and 75 to 84 years, accounting for race and comorbidity. Methods A cohort of non-Hispanic Black and non-Hispanic White women residing in the continental United States and receiving no services from a health maintenance organization was randomly selected from the Center for Medicare and Medicaid Services denominator file. The cohort was followed from 2005 to 2008 using Center for Medicare and Medicaid Services claims data. The sample included 4,476 women (weighted n = 70,731) with a diagnosis of breast cancer. Cox proportional hazard modeling was used to identify predictors of waiting times. Findings Black women had a mean of 16.7 more days between biopsy and treatment (p < .001) and 15.7 more days from mammogram to treatment (p = .003) than White women. Median duration from abnormal mammogram to treatment exceeded National Quality Measures for Breast Centers medians regardless of race, age, or number of comorbidities (overall 43 days vs. the National Quality Measures for Breast Centers value of 28 days). Conclusions Medical care delays may contribute, in part, to the widening breast cancer mortality gap between Black women and White women. Further study, with additional clinical and social information, is needed to broaden scientific understanding of racial determinants and assess the clinical significance of mammogram to treatment times among Medicare beneficiaries.

Original languageEnglish (US)
Pages (from-to)642-647
Number of pages6
JournalWomen's Health Issues
Volume26
Issue number6
DOIs
StatePublished - Nov 1 2016
Externally publishedYes

Fingerprint

Health Maintenance Organizations
Mammography
Medicare
cancer
Breast Neoplasms
Biopsy
organization
health
Centers for Medicare and Medicaid Services (U.S.)
comorbidity
Therapeutics
Comorbidity
Breast
Medicare Part B
mortality
Mortality
hydroquinone
time
medical care
determinants

ASJC Scopus subject areas

  • Health(social science)
  • Obstetrics and Gynecology
  • Public Health, Environmental and Occupational Health
  • Maternity and Midwifery

Cite this

Time from Screening Mammography to Biopsy and from Biopsy to Breast Cancer Treatment among Black and White, Women Medicare Beneficiaries Not Participating in a Health Maintenance Organization. / Selove, Rebecca; Kilbourne, Barbara; Fadden, Mary Kay; Sanderson, Maureen; Foster, Maya; Offodile, Regina; Husaini, Baqar; Mouton, Charles; Levine, Robert S.

In: Women's Health Issues, Vol. 26, No. 6, 01.11.2016, p. 642-647.

Research output: Contribution to journalArticle

Selove, Rebecca ; Kilbourne, Barbara ; Fadden, Mary Kay ; Sanderson, Maureen ; Foster, Maya ; Offodile, Regina ; Husaini, Baqar ; Mouton, Charles ; Levine, Robert S. / Time from Screening Mammography to Biopsy and from Biopsy to Breast Cancer Treatment among Black and White, Women Medicare Beneficiaries Not Participating in a Health Maintenance Organization. In: Women's Health Issues. 2016 ; Vol. 26, No. 6. pp. 642-647.
@article{d4ce11d551ce4190b42ac7515cf1dcff,
title = "Time from Screening Mammography to Biopsy and from Biopsy to Breast Cancer Treatment among Black and White, Women Medicare Beneficiaries Not Participating in a Health Maintenance Organization",
abstract = "Purpose There is a breast cancer mortality gap adversely affecting Black women in the United States. This study assessed the relationship between number of days between abnormal mammogram, biopsy, and treatment among Medicare (Part B) beneficiaries ages 65 to 74 and 75 to 84 years, accounting for race and comorbidity. Methods A cohort of non-Hispanic Black and non-Hispanic White women residing in the continental United States and receiving no services from a health maintenance organization was randomly selected from the Center for Medicare and Medicaid Services denominator file. The cohort was followed from 2005 to 2008 using Center for Medicare and Medicaid Services claims data. The sample included 4,476 women (weighted n = 70,731) with a diagnosis of breast cancer. Cox proportional hazard modeling was used to identify predictors of waiting times. Findings Black women had a mean of 16.7 more days between biopsy and treatment (p < .001) and 15.7 more days from mammogram to treatment (p = .003) than White women. Median duration from abnormal mammogram to treatment exceeded National Quality Measures for Breast Centers medians regardless of race, age, or number of comorbidities (overall 43 days vs. the National Quality Measures for Breast Centers value of 28 days). Conclusions Medical care delays may contribute, in part, to the widening breast cancer mortality gap between Black women and White women. Further study, with additional clinical and social information, is needed to broaden scientific understanding of racial determinants and assess the clinical significance of mammogram to treatment times among Medicare beneficiaries.",
author = "Rebecca Selove and Barbara Kilbourne and Fadden, {Mary Kay} and Maureen Sanderson and Maya Foster and Regina Offodile and Baqar Husaini and Charles Mouton and Levine, {Robert S.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.whi.2016.09.003",
language = "English (US)",
volume = "26",
pages = "642--647",
journal = "Women's Health Issues",
issn = "1049-3867",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Time from Screening Mammography to Biopsy and from Biopsy to Breast Cancer Treatment among Black and White, Women Medicare Beneficiaries Not Participating in a Health Maintenance Organization

AU - Selove, Rebecca

AU - Kilbourne, Barbara

AU - Fadden, Mary Kay

AU - Sanderson, Maureen

AU - Foster, Maya

AU - Offodile, Regina

AU - Husaini, Baqar

AU - Mouton, Charles

AU - Levine, Robert S.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Purpose There is a breast cancer mortality gap adversely affecting Black women in the United States. This study assessed the relationship between number of days between abnormal mammogram, biopsy, and treatment among Medicare (Part B) beneficiaries ages 65 to 74 and 75 to 84 years, accounting for race and comorbidity. Methods A cohort of non-Hispanic Black and non-Hispanic White women residing in the continental United States and receiving no services from a health maintenance organization was randomly selected from the Center for Medicare and Medicaid Services denominator file. The cohort was followed from 2005 to 2008 using Center for Medicare and Medicaid Services claims data. The sample included 4,476 women (weighted n = 70,731) with a diagnosis of breast cancer. Cox proportional hazard modeling was used to identify predictors of waiting times. Findings Black women had a mean of 16.7 more days between biopsy and treatment (p < .001) and 15.7 more days from mammogram to treatment (p = .003) than White women. Median duration from abnormal mammogram to treatment exceeded National Quality Measures for Breast Centers medians regardless of race, age, or number of comorbidities (overall 43 days vs. the National Quality Measures for Breast Centers value of 28 days). Conclusions Medical care delays may contribute, in part, to the widening breast cancer mortality gap between Black women and White women. Further study, with additional clinical and social information, is needed to broaden scientific understanding of racial determinants and assess the clinical significance of mammogram to treatment times among Medicare beneficiaries.

AB - Purpose There is a breast cancer mortality gap adversely affecting Black women in the United States. This study assessed the relationship between number of days between abnormal mammogram, biopsy, and treatment among Medicare (Part B) beneficiaries ages 65 to 74 and 75 to 84 years, accounting for race and comorbidity. Methods A cohort of non-Hispanic Black and non-Hispanic White women residing in the continental United States and receiving no services from a health maintenance organization was randomly selected from the Center for Medicare and Medicaid Services denominator file. The cohort was followed from 2005 to 2008 using Center for Medicare and Medicaid Services claims data. The sample included 4,476 women (weighted n = 70,731) with a diagnosis of breast cancer. Cox proportional hazard modeling was used to identify predictors of waiting times. Findings Black women had a mean of 16.7 more days between biopsy and treatment (p < .001) and 15.7 more days from mammogram to treatment (p = .003) than White women. Median duration from abnormal mammogram to treatment exceeded National Quality Measures for Breast Centers medians regardless of race, age, or number of comorbidities (overall 43 days vs. the National Quality Measures for Breast Centers value of 28 days). Conclusions Medical care delays may contribute, in part, to the widening breast cancer mortality gap between Black women and White women. Further study, with additional clinical and social information, is needed to broaden scientific understanding of racial determinants and assess the clinical significance of mammogram to treatment times among Medicare beneficiaries.

UR - http://www.scopus.com/inward/record.url?scp=84994422992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994422992&partnerID=8YFLogxK

U2 - 10.1016/j.whi.2016.09.003

DO - 10.1016/j.whi.2016.09.003

M3 - Article

C2 - 27773529

AN - SCOPUS:84994422992

VL - 26

SP - 642

EP - 647

JO - Women's Health Issues

JF - Women's Health Issues

SN - 1049-3867

IS - 6

ER -